The GH Research Society held its 16th Workshop on the topic of Safety of GH Treatment in Cancer and Intracranial Tumor Survivors in Children and Adults.
This invitation-only workshop was performed through a web-based platform. We had adapted the schedule of this web-based structure with short online meetings taking place on three different occasions last year (June 9th and 16th, and September 29th). The workshop was organized with the support of the European Society of Endocrinology. Other major endocrine societies had also been invited to nominate delegates to the workshop.
Additionally, representatives from the regulatory agencies, EMA and FDA, attended. A review paper on the topic had been written by members of the program organizing committee, and it was distributed to the delegates prior to the start of the meeting. The format of each workshop had been modified over the years, but the backbone of plenary lectures set the scene followed by breakout group discussions of more specific themes or questions.
The final session was devoted to drafting a statement summarizing the outcome of the workshop that was submitted for publication. GRS had published the results of its previous 15 workshops that had ‘stood the test of time’.